Natera logo

Natera Stock

StockStock
ISIN: US6323071042
Ticker: NTRA
US6323071042
NTRA

Price

Frequently asked questions

What is Natera's market capitalization?

The market capitalization of Natera is $15.67B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Natera?

Natera's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$2.465. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Natera's stock?

Currently, 17 analysts cover Natera's stock, with a consensus target price of $123.31. Analyst ratings provide insights into the stock's expected performance.

What is Natera's revenue over the trailing twelve months?

Over the trailing twelve months, Natera reported a revenue of $1.36B.

What is the EBITDA for Natera?

Natera's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$284.86M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Natera?

Natera has a free cash flow of -$117.81M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Natera's stock?

The 5-year beta for Natera is 1.52. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Natera have, and what sector and industry does it belong to?

Natera employs approximately 3,282 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Natera's shares?

The free float of Natera is 118.58M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 
$15.67B

5Y beta

 
1.52

EPS (TTM)

 
-$2.465

Free Float

 
118.58M

Revenue (TTM)

 
$1.36B

EBITDA (TTM)

 
-$284.86M

Free Cashflow (TTM)

 
-$117.81M

Pricing

52W span
$40.61$133.54

Analyst Ratings

The price target is $123.31 and the stock is covered by 17 analysts.

Buy

16

Hold

0

Sell

1

Information

Natera, Inc. is a diagnostics company, which is focused on the development and commercialization of molecular testing services, applying its technology in the fields of women’s health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, Empower, and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company’s algorithms and bioinformatics in order to validate and launch tests based on the Company’s technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.

3,282

Biotechnology & Drugs

Health Care

Identifier

ISIN

US6323071042

Primary Ticker

NTRA
Join the conversation